REGENERON PHARMACEUTICALS, INC. — Form 8-K
Filed September 30, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
CEO Leonard Schleifer received 2.7M PSUs and Chief Scientific Officer George Yancopoulos received 2.9M PSUs, both granted September 24, 2026. Awards span 10 years (2026–2035) with three performance tracks: (1) activity-based PSUs for FDA filings (10,000 per filing) and approvals (15,000 per approval); (2) revenue-based PSUs scaled to $10B–$30B in new product sales (0–1.8M PSUs annually); (3) relative TSR modifier (±20% adjustment vs. NASDAQ Biotech Index). No additional equity awards permitted either executive through December 31, 2035. Shares subject to 80/20 holdback (20% retained until 2036) and mandatory holding period through certification date.
Why this rating
Material but not transformational. ~5.6M PSUs at $751.73/share = ~$4.2B notional value (7.7% of $54.8B market cap). Aligns founder compensation with 10-year pipeline/revenue goals; no new cash outlay. Reinforces long-term commitment but stock is dilutive and contingent on execution. Moderate positive for governance (succession planning clause), neutral-to-slightly-negative for shareholders (dilution risk, no equity awards for top talent through 2035).
Extracted items
Price action (we called it neutral)
before filing · preread $753.00 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.